Early Ketamine to Treat Refractory Status Epilepticus
- Andreas H. Kramer
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Management of refractory status epilepticus (SE) involves administration of intravenous γ-aminobutyric acid (GABAA) receptor agonists, such as benzodiazepines, barbiturates, or propofol. Animal models suggest that reductions in synaptic GABAA receptors may cause these drugs to become less effective as the duration of SE increases. This may explain the large doses that are commonly required to control seizures, which in turn contributes to a high incidence of complications, including hypotension and the need for vasopressors. In contrast, expression of excitatory N-methyl-d-aspartate (NMDA) receptors increases with prolonged SE and their stimulation by glutamate may propagate seizure activity. Ketamine is a NMDA-receptor antagonist that is considered promising as treatment for refractory SE. Compared with other anaesthetic drugs, ketamine produces less hypotension.
This report describes a patient who developed worsening hypotension with escalating doses of midazolam and propofol in the context of non-convulsive SE. He was therefore treated with ketamine within hours of being diagnosed.
Ketamine was immediately efficacious at reducing the frequency, amplitude, and duration of seizures. The dose was rapidly titrated upwards using quantitative continuous EEG monitoring, until seizures were completely abolished. SE did not recur with weaning of sedatives and he went on to have an excellent recovery. A small number of previous reports have found ketamine to abort late SE. In most cases, ketamine was administered several days into the course, and outcomes were poor even though seizures were controlled.
Larger series and phase I clinical trial(s) of ketamine for treatment of refractory SE seem warranted.
- Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922–30. CrossRef
- Claassen J, Hiersch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146–53. CrossRef
- Goodkin HP, Yeh JL, Kapur J. Status epilepticus increases the intracellular accumulation of GABAA receptors. J Neurol. 2005;25:5511–20.
- Mazarati AM, Wasterlain CG. N-methyl-d-aspartate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett. 1999;265:187–90. CrossRef
- Kapur J, Lothman EW. NMDA receptor activation mediates the loss of GABAergic inhibition induced by recurrent seizures. Epilepsy Res. 1990;5:103–11. CrossRef
- Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117–42. CrossRef
- Walker MC, Howard RS, Smith SJ, et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. Q J Med. 1996;89:913–20.
- Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol. 1997;9:269–72. CrossRef
- Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51:1765–6.
- Nathan B, Smith TL, Bleck TB. The use of ketamine in the treatment of refractory status epilepticus. Neurology. 2002;3:A197.
- Ubogu EE, Sagar SM, Lerner AJ, et al. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4:70–5. CrossRef
- Pruss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219–22. CrossRef
- Hsieh CY, Sung PS, Tsai JJ, Huang CW. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharm. 2010;33:165–7. CrossRef
- Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723–6. CrossRef
- Stewart CP, Otsubo H, Ochi A, et al. Seizure identification in the ICU using quantitative EEG displays. Neurology. 2010;75:1501–8. CrossRef
- Ko SB, Ortega-Gutierrez S, Choi HA, et al. Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest. Arch Neurol. 2011;68:1323–6. CrossRef
- Stewart LS, Persinger MA. Ketamine prevents learning impairment when administered immediately after status epilepticus onset. Epilepsy Behav. 2001;2:585–91. CrossRef
- Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia. 2008;49:248–55. CrossRef
- Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37:3024–30. CrossRef
- Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia. 2004;45:757–63. CrossRef
- Vasile B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29:1417–25. CrossRef
- Mewasingh LD, Skhara T, Aeby A, et al. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12:483–9. CrossRef
- Kramer U, Shorer Z, Ben-Zeev B, et al. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20:184–7.
- Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly be reversed uptake. Nature. 2000;403:316–21. CrossRef
- Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8. CrossRef
- Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology. 2011;76:1750–7. CrossRef
- Early Ketamine to Treat Refractory Status Epilepticus
Volume 16, Issue 2 , pp 299-305
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Status epilepticus
- Industry Sectors
- Andreas H. Kramer (1) (2)
- Author Affiliations
- 1. Department of Critical Care Medicine, University of Calgary, ICU Administration, Ground Floor, McCaig Tower, 3134 Hospital Dr NW, Calgary, AB, T2N 2T9, Canada
- 2. Department of Clinical Neurosciences, University of Calgary, ICU Administration, Ground Floor, McCaig Tower, 3134 Hospital Dr NW, Calgary, AB, T2N 2T9, Canada